Amyris Acquires Oobli to Boost Sweet Protein and Fermentation Tech

Amyris, a leader in biomanufacturing, is set to acquire Oobli, a company known for its innovative sweet protein technology. This strategic move is poised to expand Amyris' footprint in the alternative sweeteners market, leveraging Oobli's fermentation expertise to meet the growing demand for healthier food and beverage options.

What Happened
Amyris announced its agreement to acquire Oobli, a developer of fermentation-produced sweet proteins, which are used as sugar substitutes in food and beverages. This acquisition aims to merge Amyris' strain engineering and industrial fermentation capabilities with Oobli's proprietary sweet protein technology. The transaction is expected to close in the coming weeks. Amyris, which recently expanded its manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil, plans to use its resources to accelerate the adoption of Oobli’s ingredients across various markets. The companies assure that existing customer commitments will continue without interruption.

Oobli has spent a decade perfecting its fermentation processes to produce sweet proteins from rare fruits and berries, such as Oubli Fruit, Serendipity Berry, and Katemfe Fruit. These proteins, known as brazzein, monellin, and thaumatin, are significantly sweeter than conventional sugar, offering a healthier alternative that doesn't cause blood sugar spikes. Oobli's ingredients have achieved GRAS status under the FDA framework, making them viable for use in multiple food and beverage categories.

What This Means for Your Business
For businesses in the AECM and government contracting sectors, this acquisition signals potential shifts in procurement strategies and supply chains. Companies developing or manufacturing food and beverage products can explore new formulations that incorporate Oobli's sweet proteins, potentially reducing sugar content while maintaining flavor integrity. This could lead to cost savings and enhanced product appeal in a market increasingly focused on health-conscious consumers. Additionally, Amyris' enhanced manufacturing capabilities could provide more reliable and scalable supply chains for these innovative ingredients.

Compliance officers and procurement directors should note the regulatory status of Oobli's sweet proteins, which are recognized as safe by both the FDA and FEMA for specific uses. The integration of these ingredients into product lines may require adherence to specific regulatory conditions, impacting compliance strategies and operational logistics.

What US Operators Should Watch
US operators should monitor the closing of this acquisition in the upcoming weeks and Amyris' subsequent integration plans. This could affect procurement windows and timelines for incorporating these sweet proteins into product lines. Additionally, companies should stay informed about any updates in FDA regulations or GRAS status changes that may impact the use of Oobli's ingredients in various applications. As the market for alternative sweeteners evolves, keeping an eye on competitive positioning and potential collaborations with Amyris may offer strategic advantages.

Source: https://pulse2.com/amyris-acquisition-of-oobli-to-expand-sweet-protein-technology-and-precision-fermentation-capabilities/